ARCHIVES

Switch To NTP Holds Down Entry Of New Compounds; Obey Supports NCI On Need For More Positions

This article is from The Cancer Letter archive.

Vol. 05 No. 11 | March 16, 1979

Download PDF Visit The Full Archive

Related Articles

NCI advisors approve recompetition of $62 million phase II contracts program.

November 19, 2004

FDA Grants Accelerated Approval To Mekinist-Tafinlar Combination

January 31, 2014

Program Project Guidelines Listed

March 18, 1977

Funding Opportunities: Lymphoma Fellowship

June 8, 2001

Anonymous $100 Million Gift Moves OHSU Within $82 Million Of Reaching $1 Billion Goal

August 1, 2014

Avastin-Zybrestat Combination Increases Progression-Free Survival in Phase II Trial

March 28, 2014